What is Lifesci Capital’s Estimate for DFTX FY2026 Earnings?

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Analysts at Lifesci Capital increased their FY2026 earnings per share estimates for Definium Therapeutics in a report issued on Monday, June 22nd. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($2.30) per share for the year, up from their previous estimate of ($2.32). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.30) per share. Lifesci Capital also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.54) EPS.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23).

Several other equities analysts also recently weighed in on the stock. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. HC Wainwright increased their price target on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. Finally, Oppenheimer set a $60.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $46.08.

Definium Therapeutics Price Performance

Definium Therapeutics stock opened at $36.18 on Wednesday. Definium Therapeutics has a 52 week low of $6.40 and a 52 week high of $39.16. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm’s 50-day simple moving average is $23.28 and its 200 day simple moving average is $18.75. The firm has a market capitalization of $3.61 billion, a PE ratio of -14.53 and a beta of 2.37.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DFTX. Boxer Capital Management LLC purchased a new stake in Definium Therapeutics in the 3rd quarter worth approximately $1,928,000. Royce & Associates LP acquired a new position in Definium Therapeutics in the 3rd quarter valued at $955,000. Rosalind Advisors Inc. lifted its stake in shares of Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Definium Therapeutics during the 3rd quarter worth $609,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of Definium Therapeutics during the 4th quarter worth $117,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium’s Phase 3 Emerge trial for DT120 met the primary endpoint and all key secondary endpoints, reinforcing confidence in the company’s lead depression program. Article: Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
• Positive Sentiment: Robert W. Baird raised its price target on DFTX and maintained an outperform rating, while Needham also lifted its target and kept a buy rating, signaling improving Wall Street sentiment. Article: Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
• Neutral Sentiment: The company plans a webcast to discuss the trial data, which may provide more detail on durability, safety, and next steps for the program. Article: Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could pressure the stock if investors focus on dilution and financing needs. Article: Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.